Search Results - "Kipnes, M"

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin by Hermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P.

“…Aim:  To assess the efficacy and safety of a 24‐week treatment with sitagliptin, a highly selective once‐daily oral dipeptidyl peptidase‐4 (DPP‐4) inhibitor,…”
Get full text

A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes by Leifke, E, Naik, H, Wu, J, Viswanathan, P, DeManno, D, Kipnes, M, Vakilynejad, M

“…G‐protein‐coupled receptor 40 (GPR40), highly expressed in pancreatic β‐cells, mediates free fatty acid (FFA)‐induced insulin secretion. This phase I,…”
Get full text

Macimorelin (AEZS-130)-Stimulated Growth Hormone (GH) Test: Validation of a Novel Oral Stimulation Test for the Diagnosis of Adult GH Deficiency by Garcia, J. M, Swerdloff, R, Wang, C, Kyle, M, Kipnes, M, Biller, B. M. K, Cook, D, Yuen, K. C. J, Bonert, V, Dobs, A, Molitch, M. E, Merriam, G. R

“…Context: In the absence of panhypopituitarism and low serum IGF-I levels, the diagnosis of adult GH deficiency (AGHD) requires confirmation with a GH…”
Get full text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy by Pratley, R. E., Kipnes, M. S., Fleck, P. R., Wilson, C., Mekki, Q.

“…Aim:  To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in combination with glyburide…”
Get full text

one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes by Kipnes, M.S, Hollander, P, Fujioka, K, Gantz, I, Seck, T, Erondu, N, Shentu, Y, Lu, K, Suryawanshi, S, Chou, M, Johnson-Levonas, A.O, Heymsfield, S.B, Shapiro, D, Kaufman, K.D, Amatruda, J.M

“…Aim: To evaluate the efficacy and safety of taranabant in overweight and obese patients with type 2 diabetes mellitus (T2DM). Methods: This was a multicenter,…”
Get full text

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes by Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., Ehlers, M. R.

“…Aim: To evaluate the dose–response relationship of the recombinant glucagon‐like peptide‐1 (7‐36) amide (rGLP‐1) administered by continuous subcutaneous…”
Get full text

Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes by Chacra, A. R., Kipnes, M., Ilag, L. L., Sarwat, S., Giaconia, J., Chan, J.

“…Diabet. Med. 27, 563–569 (2010) Aims  The efficacy of two basal insulins, insulin lispro protamine suspension (ILPS) and insulin detemir, was compared in…”
Get full text

Immunomodulation in Type 1 Diabetes by NBI‐6024, an Altered Peptide Ligand of the Insulin B(9−23) Epitope by Alleva, D. G., Maki, R. A., Putnam, A. L., Robinson, J. M., Kipnes, M. S., Dandona, P., Marks, J. B., Simmons, D. L., Greenbaum, C. J., Jimenez, R. G., Conlon, P. J., Gottlieb, P. A.

“…NBI‐6024 is an altered peptide ligand (APL) corresponding to the 9–23 amino acid region of the insulin B chain (B(9−23)), an epitope recognized by inflammatory…”
Get full text

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study by Kipnes, M S, Krosnick, A, Rendell, M S, Egan, J W, Mathisen, A L, Schneider, R L

“…To evaluate the efficacy and tolerability of pioglitazone in combination with a sulfonylurea in the treatment of type 2 diabetes mellitus. This 16-week,…”
Get more information

Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men by Dobs, A. S., Matsumoto, A. M., Wang, C., Kipnes, M. S.

“…SUMMARY Objective: The primary objective of the study was to compare the percentage of men with mean serum total T (Cave(0-24)) within normal range during the…”
Get full text

P02-48 A novel long acting human growth hormone (VRS-317): sustained and dose dependent biological activity in growth hormone deficient adults by Bright, G.M, Yuen, K.C.J, Conway, G.S, Popovic-Brkic, V, Merriam, G.R, Bailey, T, Hamrahian, A, Biller, B.M.K, Kipnes, M, Humphriss, E, Cleland, J.L

Get full text

OR03-3 Use of an orally active ghrelin mimetic, macimorelin (AEZS-130), as a safe, simple test for adult GH deficiency: Effect of BMI on optimal cutoff by Merriam, G.R, Swerdloff, R, Wang, C, Kyle, M, Kipnes, M, Cook, D, Yuen, K, Bonert, V, Dobs, A, Molitch, M, Chen, M, Ruppel, P, Biller, B.M, Garcia, J

Get full text

Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism by Korbonits, M, Kipnes, M, Grossman, A B

“…Striant SR (marketed as Striant in the US) is a novel sustained-release mucoadhesive buccal testosterone tablet for the treatment of male hypogonadism. Striant…”
Get more information

P3 Macimorelin, an oral ghrelin-mimetic GH secretagogue, as a potential diagnostic test for adult GH deficiency by Biller, B.M.K, Yuen, K.C.J, Bonert, V, Chen, M, Dobs, A, Garcia, J.M, Kipnes, M, Molitch, M, Swerdloff, R, Wang, C, Cook, D, Altemose, I.R, Merriam, G.R

Get full text

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease by Mudaliar, Sunder, Henry, Robert R, Sanyal, Arun J, Morrow, Linda, Marschall, Hanns–Ulrich, Kipnes, Mark, Adorini, Luciano, Sciacca, Cathi I, Clopton, Paul, Castelloe, Erin, Dillon, Paul, Pruzanski, Mark, Shapiro, David

“…Background & Aims Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a semisynthetic derivative of the primary human bile acid chenodeoxycholic…”
Get full text

Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients by Jabri, N., Schalch, D. S., Schwartz, S. L., Fischer, J. S., Kipnes, M. S., Radnik, B. J., Turman, N. J., Marcsisin, V. S., Guler, H. P.

“…Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. N Jabri , D S Schalch , S L Schwartz ,…”
Get full text

Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients by JABRI, N, SCHALCH, D. S, SCHWARTZ, S. L, FISCHER, J. S, KIPNES, M. S, RADNIK, B. J, TURMAN, N. J, MARCSISIN, V. S, GULER, H.-P

“…Data from studies in diabetic rodents and evidence from clinical situations of severe resistance to insulin suggest that insulin-like growth factor I (IGF-I)…”
Get full text

Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men by Yu, Zhiling, Gupta, Suneel K., Hwang, Stephen S., Kipnes, Mark S., Mooradian, Arshag D., Snyder, Peter J., Atkinson, Linda E.

“…This open‐label, randomized, placebo lead‐in, three‐treatment crossover study in 19 hypogonadal men (27–82 years of age) evaluated dose proportionality of…”
Get full text

Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis – a randomized, multicentre, placebo‐controlled study by MCCALLUM, R. W., CYNSHI, O.

“…Summary Background  Mitemcinal is an orally active motilin agonist that could potentially improve gastric emptying. Aim  To investigate the effect of…”
Get full text

New Testosterone Buccal System (Striant) Delivers Physiological Testosterone Levels: Pharmacokinetics Study in Hypogonadal Men by Wang, Christina, Swerdloff, Ronald, Kipnes, Mark, Matsumoto, Alvin M., Dobs, Adrian S., Cunningham, Glenn, Katznelson, Laurence, Weber, Thomas J., Friedman, Theodore C., Snyder, Peter, Levine, Howard L.

“…A new mucoadhesive testosterone buccal system (Striant), 30 mg testosterone (T), was applied twice daily in 82 hypogonadal men for 3 months. Serum T, free T,…”
Get full text